2019 Volume 62 Issue 5 Pages 315-321
The purpose of this retrospective observational study is to analyze the clinical course of sensor augmented pump (SAP) therapy after switching from insulin pump therapy and to evaluate the predictors of the therapeutic effects of SAP therapy. Twenty-two type 1 diabetes patients who received SAP therapy for more than one year after switching from insulin pump therapy were enrolled. HbA1c levels were unchanged at 6 months and significantly improved at 12 months. The HbA1c levels at 6 months were decreased in 14 patients and unchanged or increased in the other 8 patients. In the latter group with unchanged or increased HbA1c levels at 6 months, the mean HbA1c level at the induction of SAP therapy was significantly lower and the percentage of patients with SMBG <70mg/dL before SAP therapy was higher in comparison to the former group. A multiple regression analysis showed a significant negative correlation between the change in %TBD (6M) and the change in the HbA1c level (6M). Conclusively, in patients with frequent hypoglycemia, we should evaluate the therapeutic effects based on various parameters, such as average sensor glucose levels and AUC <70mg/dL, since it is possible that the HbA1c level may transiently increase after the induction of SAP therapy in such cases.
